We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · January 19, 2022

Predictive Biomarkers of Overall Survival in Patients With RCC Treated With Interferon Alpha ± Bevacizumab

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Predictive biomarkers of overall survival in patients with renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance)
Clin. Cancer Res 2021 Dec 29;[EPub Ahead of Print], AB Nixon, S Halabi, Y Liu, MD Starr, JC Brady, I Shterev, B Luo, HI Hurwitz, PG Febbo, BI Rini, H Beltran, EJ Small, MJ Morris, DJ George

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading